Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 11;75(2):242–252. doi: 10.1002/art.42391

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Adjusted mean percentage change in interferon gene signature from baseline (BL) over 44‐week follow‐up in patient groups receiving deucravacitinib 3 mg twice daily (BID), deucravacitinib 6 mg twice daily, deucravacitinib 12 mg once daily (QD), or placebo for treatment of systemic lupus erythematosus. Vertical bars indicate 95% confidence intervals (95% CIs). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.42391/abstract.